Search Results 681-690 of 14754 for anti-TNF drugs

1. Terbinafine (Oral Route) Description and Brand Names - Mayo Clinic

   Terbinafine belongs to the group of medicines called antifungals. It is used to treat fungus infections of the scalp, body, groin (jock itch), feet (athlete's ...

2. Antihemophilic Factor (Intravenous Route) Precautions - Mayo Clinic

   Precautions. Drug information provided by: Merative, Micromedex®. It is very important that your doctor check you or your child closely while you are ...

3. Trastuzumab-Strf (Intravenous Route) Description and Brand Names - Mayo Clinic

   Descriptions. Trastuzumab-strf injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or ...

4. Therapeutic Drug Monitoring of Pembrolizumab and Nivolumab to Determine Dosages for Cancer Treatment - Mayo Clinic

   About this study. Drug monitoring of Pembrolizumaband Nivolumab for determining the pharmacokinetic (PK) profile of these medications and to provide ...

5. Milnacipran (Oral Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

6. A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - Mayo Clinic

   About this study. The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + ...

7. Targeting VEGF-Independent Proangiogenic Pathways in Anti-VEGF Refractory Renal Cell Cancer - Tumor Angiogenesis and Vascular Biology Laboratory - Mayo Clinic Research

   Mukhopadhyay's lab is developing novel treatment strategies to target these pathways for refractory and highly aggressive tumor types and for sarcomatoid renal ...

8. CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies - Mayo Clinic

   The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...

9. Mogamulizumab-Kpkc (Intravenous Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Poteligeo. Descriptions. Mogamulizumab-kpkc injection is ...

10. Neratinib (Oral Route) Proper Use - Mayo Clinic

    Continue taking these medicines for 2 cycles (56 days) of treatment with neratinib. Keep the number of your bowel movements at 1 to 2 per day and take anti- ...